FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207075966> ?p ?o ?g. }

• W4207075966 endingPage "S71" @default.
• W4207075966 startingPage "S70" @default.
• W4207075966 abstract "Abstract The pathogenesis of ulcerative colitis (UC) involves genetic susceptibility, immune-mediated tissue injury and environmental factors including disturbances of the gut microbiota. Nearly all current approved therapies modify host immunity, rather than directly targeting the microbiota. Fecal microbiota transplantation provides encouraging evidence for the therapeutic potential of gut microbiome modulation. Bacteria in the GI tract are ecologically differentiated by their ability to use specific glycans as growth substrates, making glycans a promising and safe alternative to target the microbiome. To explore this, we used an ex vivo fecal microbiota culture system to identify a synthetic glycan (KB295) with desirable microbiological activity and conducted a proof of principle study of safety and tolerability of KB295 in patients with UC. Fecal microbial communities from healthy subjects were incubated anaerobically with and without (negative control) KB295. KB295 increased short chain fatty acid (SCFA) production across ten fecal samples to a median concentration of 47.0 mM compared to 15.2 mM with the negative control in culture supernatants, including increases in acetate, propionate, and butyrate in all cases. Metagenomic sequencing of the ex vivo fecal pellets revealed that KB295 depleted pathobionts in the family Enterobacteriaceae to a median relative abundance of 10.8% compared to 38.2% with the negative control. Pathobiont depletion was associated with enrichments of diverse genera in the phyla Bacteroidetes and Firmicutes. Twelve patients with mild to moderate UC were enrolled in an open-label single-arm study with an 8-week intake of KB295. KB295 was well tolerated with generally mild adverse events, and only one AE resulted in discontinuation. The most frequently occurring adverse events were changes in bowel habit, flatulence, and headache. Fecal calprotectin and lactoferrin decreased by median values of 69.0% (n=11) and 86.0% (n=6), respectively, from screening to the end of the KB295 intake. Consistent with the ex vivo preclinical findings, of the subjects for whom we have data to date, the relative abundance of the fecal pathobiont family Enterobacteriaceae decreased from five participants, and the commensal genus Parabacteroides was enriched in four of five participants. These results establish a proof of principle for the glycobiological modulation of gut microbiome composition and function and provide insight into the potential utility of this strategy in patients with ulcerative colitis. The safety, tolerability, and encouraging evidence for reduced inflammation with KB295 call for a Phase 2 study, which is planned." @default.
• W4207075966 created "2022-01-26" @default.
• W4207075966 creator A5000963421 @default.
• W4207075966 creator A5002568737 @default.
• W4207075966 creator A5012035229 @default.
• W4207075966 creator A5015495355 @default.
• W4207075966 creator A5022912971 @default.
• W4207075966 creator A5027651687 @default.
• W4207075966 creator A5029478309 @default.
• W4207075966 creator A5045995258 @default.
• W4207075966 creator A5070763595 @default.
• W4207075966 creator A5072945263 @default.
• W4207075966 creator A5077079813 @default.
• W4207075966 creator A5086462615 @default.
• W4207075966 creator A5089846907 @default.
• W4207075966 date "2022-01-22" @default.
• W4207075966 modified "2023-10-04" @default.
• W4207075966 title "THE SYNTHETIC GLYCAN KB295 OPTIMIZES MICROBIOME COMPOSITION AND FUNCTION IN ULCERATIVE COLITIS – RESULTS FROM A PROOF OF PRINCIPLE HUMAN STUDY" @default.
• W4207075966 doi "https://doi.org/10.1093/ibd/izac015.114" @default.
• W4207075966 hasPublicationYear "2022" @default.
• W4207075966 type Work @default.
• W4207075966 citedByCount "0" @default.
• W4207075966 crossrefType "journal-article" @default.
• W4207075966 hasAuthorship W4207075966A5000963421 @default.
• W4207075966 hasAuthorship W4207075966A5002568737 @default.
• W4207075966 hasAuthorship W4207075966A5012035229 @default.
• W4207075966 hasAuthorship W4207075966A5015495355 @default.
• W4207075966 hasAuthorship W4207075966A5022912971 @default.
• W4207075966 hasAuthorship W4207075966A5027651687 @default.
• W4207075966 hasAuthorship W4207075966A5029478309 @default.
• W4207075966 hasAuthorship W4207075966A5045995258 @default.
• W4207075966 hasAuthorship W4207075966A5070763595 @default.
• W4207075966 hasAuthorship W4207075966A5072945263 @default.
• W4207075966 hasAuthorship W4207075966A5077079813 @default.
• W4207075966 hasAuthorship W4207075966A5086462615 @default.
• W4207075966 hasAuthorship W4207075966A5089846907 @default.
• W4207075966 hasBestOaLocation W42070759661 @default.
• W4207075966 hasConcept C100544194 @default.
• W4207075966 hasConcept C104317684 @default.
• W4207075966 hasConcept C126322002 @default.
• W4207075966 hasConcept C143121216 @default.
• W4207075966 hasConcept C150903083 @default.
• W4207075966 hasConcept C15151743 @default.
• W4207075966 hasConcept C203014093 @default.
• W4207075966 hasConcept C207001950 @default.
• W4207075966 hasConcept C26291073 @default.
• W4207075966 hasConcept C2776979534 @default.
• W4207075966 hasConcept C2777385719 @default.
• W4207075966 hasConcept C2777695942 @default.
• W4207075966 hasConcept C2778260677 @default.
• W4207075966 hasConcept C2779134260 @default.
• W4207075966 hasConcept C2780206646 @default.
• W4207075966 hasConcept C2780305828 @default.
• W4207075966 hasConcept C2780479503 @default.
• W4207075966 hasConcept C31903555 @default.
• W4207075966 hasConcept C42062724 @default.
• W4207075966 hasConcept C523546767 @default.
• W4207075966 hasConcept C539455810 @default.
• W4207075966 hasConcept C54355233 @default.
• W4207075966 hasConcept C55493867 @default.
• W4207075966 hasConcept C60644358 @default.
• W4207075966 hasConcept C61716771 @default.
• W4207075966 hasConcept C71924100 @default.
• W4207075966 hasConcept C86803240 @default.
• W4207075966 hasConcept C89423630 @default.
• W4207075966 hasConcept C91478284 @default.
• W4207075966 hasConceptScore W4207075966C100544194 @default.
• W4207075966 hasConceptScore W4207075966C104317684 @default.
• W4207075966 hasConceptScore W4207075966C126322002 @default.
• W4207075966 hasConceptScore W4207075966C143121216 @default.
• W4207075966 hasConceptScore W4207075966C150903083 @default.
• W4207075966 hasConceptScore W4207075966C15151743 @default.
• W4207075966 hasConceptScore W4207075966C203014093 @default.
• W4207075966 hasConceptScore W4207075966C207001950 @default.
• W4207075966 hasConceptScore W4207075966C26291073 @default.
• W4207075966 hasConceptScore W4207075966C2776979534 @default.
• W4207075966 hasConceptScore W4207075966C2777385719 @default.
• W4207075966 hasConceptScore W4207075966C2777695942 @default.
• W4207075966 hasConceptScore W4207075966C2778260677 @default.
• W4207075966 hasConceptScore W4207075966C2779134260 @default.
• W4207075966 hasConceptScore W4207075966C2780206646 @default.
• W4207075966 hasConceptScore W4207075966C2780305828 @default.
• W4207075966 hasConceptScore W4207075966C2780479503 @default.
• W4207075966 hasConceptScore W4207075966C31903555 @default.
• W4207075966 hasConceptScore W4207075966C42062724 @default.
• W4207075966 hasConceptScore W4207075966C523546767 @default.
• W4207075966 hasConceptScore W4207075966C539455810 @default.
• W4207075966 hasConceptScore W4207075966C54355233 @default.
• W4207075966 hasConceptScore W4207075966C55493867 @default.
• W4207075966 hasConceptScore W4207075966C60644358 @default.
• W4207075966 hasConceptScore W4207075966C61716771 @default.
• W4207075966 hasConceptScore W4207075966C71924100 @default.
• W4207075966 hasConceptScore W4207075966C86803240 @default.
• W4207075966 hasConceptScore W4207075966C89423630 @default.
• W4207075966 hasConceptScore W4207075966C91478284 @default.
• W4207075966 hasIssue "Supplement_1" @default.
• W4207075966 hasLocation W42070759661 @default.
• W4207075966 hasOpenAccess W4207075966 @default.

• next